Price | 9057€+ Login to see price |
Organism | Human |
Product Type | Organoid + TIL |
Tissue | Adaptive |
Disease | – |
Applications
Cancer Organoid
Colorectal Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Breast Cancer
Cholangiocarcinoma
Gastric Cancer
Ovarian Cancer
With the global rise of K-beauty, the cosmetics industry continues to grow steadily. Since the ban on animal testing for cosmetics in Korea in 2017, various alternative testing methods have...
Traditional microscopy methods often require fluorescent labeling to analyze cellular structures, which can be time-consuming and invasive. In contrast, our HT-X1 system allows for high-resolution visualization of cellular morphology without...
Traditional protein analysis has primarily focused on quantifying expression levels within tissue samples. However, recent advances in spatial analysis techniques have shifted attention toward evaluating not only expression levels, but...
We conducted a study focused on identifying disease-related markers using patient-derived tissue samples. However, traditional methods limited our ability to analyze multiple candidate markers simultaneously, and the limited availability of...
Tumor-infiltrating lymphocytes (TILs) are immune cells in cancer tissues with the potential to either eliminate or aid in cancer growth.
Immunotherapeutics can reactivate exhausted TILs, allowing them to attack cancer cells.
Direct extraction and cultivation of TILs provide an evaluation solution for immunotherapeutics, and the extraction yield can predict their responsiveness, considering potential absence due to extraction yield or unique cancer characteristics.
Overall efficacy (Death cells)
When evaluating the efficacy of atezolizumab in co-culture conditions with tumor organoids and tumor-infiltrating lymphocytes or tumor organoids and T cells derived from PBMCs, higher tumor organoid killing was observed in conditions without co-culture with tumor-infiltrating lymphocytes or T cells.
The method of evaluating efficacy by treating a specific mixture of tumor organoids and tumor-infiltrating lymphocytes with anticancer drugs is still at the research level globally, and our company uniquely holds patents and commercialization services related to this.
Make your research shine brighter through the only service of its kind in the world.
Lambda Biologics GmbH
Deutscher Platz 5 c, 04103, Leipzig, Germany
info@lambdabiologics.com
